CONTACT US

Email.  info@prilenia.com

Tel.  +972-77-5558482

IMPROVING THE LIVES

OF PATIENTS AND

THEIR FAMILIES

WHO WE ARE

Improving the lives of patients and their families, by developing treatments for neurodegenerative and neurodevelopmental disorders, lies at the heart of Prilenia’s mission.

 

We are a clinical stage biotech startup, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is the founder of five biotech companies and was previously President of Global R&D and Chief Scientific Officer at Teva. He has directed the development of multiple innovative drug products leading to 35 approvals between 2012-2018.

Our lead asset is Pridopidine, a first-in-class drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently in Phase 2 clinical development for the treatment of patients with Parkinson’s Disease suffering from Levodopa Induced Dyskinesia (PD-LID). We are planning to initiate a phase 3 trial in Huntington Disease in the near future.  

Prilenia is based in Herzliya, Israel and in Boston, MA.